Is the newly approved oral PCSK9 Inhibitor, Lipfendra, as clinically efficacious as injectable versions of the drug such as Repatha?

While this new cholesterol-lowering agent, enlicitdie, has been shown to be very effective, we cannot say it is "as efficacious" as PCSK9 monoclonal antibodies. The studies were done in different populations, with different baseline LDL levels, different potential concomitant medications, etc. The o...

Enlicitide (Lipfendra) was shown in recent clinical trials (Navar et al., PMID 41879224) to reduce LDL-C by 57% compared with placebo.

In their Phase 3 clinical trials, alirocumab (Praluent) (Robinson et al., PMID 25773378) lowered LDL-C 62%, evolocumab (Repatha) (Blom et al., PMID 24678979) lowered ...

In the published trials so far, it is about as potent as the injectables. Without head-to-head studies, we cannot say more than this, but it appears equal. The CVD outcome trial is underway but is almost certain to be beneficial, as lowering LDL is almost always good. Safety seems good, but the much...